Coherus Biosciences | CHRS - Beneficio Bruto En Ventas

Precio De Mercado
1.59
Cambio Diario
0.07 4.28%
Mensual
-5.09%
Anual
66.47%
Q1 Expectativa
1.47




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.48B 307M 2025-09
Baxter International USD 577M 373M 2025-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Fujifilm JPY 347.51B 14.74B 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Merck USD 13.42B 431M 2025-09
Myriad Genetics USD 146.8M 3M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xencor USD 21M 22.61M 2025-09
Zoetis USD 1.64B 73M 2025-12